Arts syndrome is caused by loss-of-function mutations in PRPS1

C (p.L152P) in the Dutch family and c.398A-->C (p.Q133P) in the Australian family. Both mutations result in a loss of phosphoribosyl pyrophosphate synthetase 1 activity, as was shown in silico by molecular modeling and was shown in vitro by phosphoribosyl pyrophosphate synthetase activity assays in erythrocytes and fibroblasts from patients. This is in contrast to the gain-of-function mutations in PRPS1 that were identified previously in PRPS-related gout. The loss-of-function mutations of PRPS1 likely result in impaired purine biosynthesis, which is supported by the undetectable hypoxanthine in urine and the reduced uric acid levels in serum from patients. To replenish low levels of purines, treatment with S-adenosylmethionine theoretically could have therapeutic efficacy, and a clinical trial involving the two affected Australian brothers is currently underway. -->
Popis souboru: application/pdf
ISSN: 0002-9297
Přístupová URL adresa: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95fb47de2db30beb1d5beb79e865764a
https://hdl.handle.net/2066/35095
Rights: OPEN
Přírůstkové číslo: edsair.doi.dedup.....95fb47de2db30beb1d5beb79e865764a
Autor: John A. Duley, Linda S. Weaving, André B.P. van Kuilenburg, Sander B. Nabuurs, Michael Egmont-Petersen, Hans van Bokhoven, Robert A. Ouvrier, Lida Zoetekouw, Melissa Roeffen, Kelly L. Williams, Jennifer A. Donald, Ben C.J. Hamel, Arjan P.M. de Brouwer, Ron A. Wevers, Dorien Lugtenberg, Martijn J.G. Banning, John Christodoulou
Přispěvatelé: AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA -Cancer Center Amsterdam, Laboratory Genetic Metabolic Diseases
Rok vydání: 2007
Předmět:
Male
Candidate gene
Erythrocytes
Genetics and epigenetic pathways of disease [NCMLS 6]
Genetic Linkage
Protein Conformation
Neuroinformatics [DCN 3]
medicine.disease_cause
chemistry.chemical_compound
Perception and Action [DCN 1]
Missense mutation
Genetics(clinical)
Genetics (clinical)
Genetics
Mutation
Phosphoribosyl pyrophosphate
Syndrome
Hypotonia
Pedigree
Muscle Hypotonia
Female
medicine.symptom
Functional Neurogenomics [DCN 2]
Ataxia
Energy and redox metabolism [NCMLS 4]
Bioinformatics
Mutation
Missense

Biology
Article
Cell Line
Genomic disorders and inherited multi-system disorders [IGMD 3]
Optic Atrophies
Hereditary

Intellectual Disability
Ribose-Phosphate Pyrophosphokinase
medicine
Humans
Hearing Loss
Chromosomes
Human
X

Arts syndrome
Fibroblasts
Glycostation disorders [IGMD 4]
Molecular biology
Neuromuscular development and genetic disorders [UMCN 3.1]
Gene expression profiling
chemistry
Genetic defects of metabolism [UMCN 5.1]
Purines
Cellular energy metabolism [UMCN 5.3]
Zdroj: American Journal of Human Genetics, 81, 3, pp. 507-18
American Journal of Human Genetics, 81, 507-18
American journal of human genetics, 81(3), 507-518. Cell Press
ISSN: 0002-9297
Popis: Contains fulltext : 35096.pdf (Publisher’s version ) (Closed access) Arts syndrome is an X-linked disorder characterized by mental retardation, early-onset hypotonia, ataxia, delayed motor development, hearing impairment, and optic atrophy. Linkage analysis in a Dutch family and an Australian family suggested that the candidate gene maps to Xq22.1-q24. Oligonucleotide microarray expression profiling of fibroblasts from two probands of the Dutch family revealed reduced expression levels of the phosphoribosyl pyrophosphate synthetase 1 gene (PRPS1). Subsequent sequencing of PRPS1 led to the identification of two different missense mutations, c.455T-->C (p.L152P) in the Dutch family and c.398A-->C (p.Q133P) in the Australian family. Both mutations result in a loss of phosphoribosyl pyrophosphate synthetase 1 activity, as was shown in silico by molecular modeling and was shown in vitro by phosphoribosyl pyrophosphate synthetase activity assays in erythrocytes and fibroblasts from patients. This is in contrast to the gain-of-function mutations in PRPS1 that were identified previously in PRPS-related gout. The loss-of-function mutations of PRPS1 likely result in impaired purine biosynthesis, which is supported by the undetectable hypoxanthine in urine and the reduced uric acid levels in serum from patients. To replenish low levels of purines, treatment with S-adenosylmethionine theoretically could have therapeutic efficacy, and a clinical trial involving the two affected Australian brothers is currently underway.
Databáze: OpenAIRE